Skip to main content

Table 1 Patients’ characteristics in primary HCC (cohort P) and secondary HCC (cohort S) from mCRC

From: Alternative splicing of estrogen receptor alpha in hepatocellular carcinoma

Clinical features Cohort P (n = 76) Cohort S (n = 32) P value
Age (y) ≤58 32 13 0.887
>58 44 19  
Gender Female 39 14 0.473
Male 37 18  
Liver cirrhosis No 26 31 0.000
Yes 50 1  
HBsAg Negative 17 30 0.000
Positive 59 2  
Preoperative liver function (Child-Pugh) A 73 32 0.553
NA 3 0  
AFP ≤18 ng/ml 33 30 0.000
>18 ng/ml 42 2  
Tumor size ≤5 cm 51 26 0.138
>5 cm 25 6  
Tumor number Single 61 20 0.052
Multiple 15 12  
Vascular invasion No 63 29 0.384
Yes 13 3  
Pathological Grade Well 10 0 NA
Moderate 58 1  
Poor 8 1  
NA 0 30  
Neo-adjuvant treatments before operation No 72 28 0.233
Yes 4 4  
Adjuvant treatments after operation Yes 18 18 0.001
No 58 14  
Intra-hepatic recurrence No 44 29 0.001
Yes 32 3  
Extra-hepatic metastasis No 63 26 0.838
Yes 13 6  
AJCC Stage 1 52 NA NA
2 16 NA  
3 + 3A 8 NA  
  1. Abbreviations: AFP alpha-fetoprotein, AJCC American Joint Committee on Cancer, NA not available; Neo-adjuvant treatments before operation, including chemotherapy, preoperative portal vein embolization (PVE) and transcatheter arterial chemoembolization (TACE); Adjuvant treatments after operation, including lipiodol-iodine-131, chemotherapy, TACE
  2. Significant data are highlighted in bold